An Investigation Into Beneficial Effects of Interferon Beta 1a, Compared to Interferon Beta 1b And The Base Therapeutic Regiment in Moderate to Severe COVID-19: A Randomized Clinical Trial

• Status: Completed
• Trial end date: 2020-04-27
• Target enrollment: 0
• Participant gender: All

Summary

The present study is a randomized clinical trial, with the approval of the ethics committee will be conducted on patients who have a positive test confirming COVID-19 in Loghman Hakim Medical Education Center in Tehran. Patients will be randomly assigned to the three arms of the study and after completing the course of treatment and collecting and analyzing the necessary information from each patient, the results of the study will be published both on this site and in the form of an article in a reputable international journal.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Shahid Beheshti University of Medical Sciences
• Treatments: Hydroxychloroquine; Interferon beta-1a; Interferon beta-1b; Interferon-beta; Interferons; Lopinavir; Ritonavir

Criteria

Inclusion Criteria:

• Age ≥ 18

• COVID-19 Confirmed Cases By Means of RT-PCR

• Oxygen saturation (SPO2) ≤ 93% OR respiratory rate ≥ 24

• At least one of the following: Calibrated contactless infrared forehead thermometry temperature of ≥37.8, cough, sputum production, nasal discharge, myalgia, headache or fatigue on admission.

• Time of onset of the symptoms should be acute ( Days ≤ 14)

Exclusion Criteria:

• Refusal to participate expressed by patient or legally authorized representative if they are present

• Patients with prolonged QT or PR intervals, Second or Third Degree heart block, Arrhythmias including torsade de pointes

• Patients using drugs with potential interaction with Hydroxychloroquine + Lopinavir/Ritonavir, Interferon-β 1a، Interferon-β 1b.

• Pregnant or lactating women.

• History of alcohol or drug addiction in the past 5 years.

• Blood ALT/AST levels > 5 times the upper limit of normal on laboratory results.